A 35-year-old female living with AIDS presented with oral thrush 3 months after the initiation of antiretroviral therapy (ART). On investigation, it was found to be due to Candida albicans. She was started on fluconazole. After 4 months on ART, she presented with fever. Blood culture was performed. After 4 days, she expired due to septic shock. Two days after her death, C albicans strain was isolated from the blood culture which was similar to the C albicans strain (by DNA fingerprinting) isolated from oral thrush. Both strains of C albicans were found to be resistant to fluconazole by broth microdilution method. A high index of suspicion in high-risk patients along with early and aggressive management of the patient with antigen detection would go a long way in the management of these patients. Guidelines for treatment of candidiasis need to be re-evaluated, keeping in mind the increasing emergence of resistance to azoles and its effect on morbidity outcome.
Introduction
Invasive fungal infections, such as candidemia, caused by Candida species are on the rise. 1, 2 Candidemia is not only associated with high mortality (30%-40%) but also extends the length of hospital stay and increases the costs of medical care. 1 Patients with candidemia usually present with acute septic syndrome that is indistinguishable from bacteremia, but they may also exhibit a more indolent course manifested by fever of unknown origin. The clinical presentation of patients with sepsis caused by Candida albicans and Non-albicans Candida (NAC) is indistinguishable. 1 Candida albicans remains the most common species causing candidemia, but the proportion caused by NAC including C tropicalis, C glabrata, C parapsilosis, and C guilliermondii s also increasing. 1, 3 Major risk factors for candidemia include use of central venous catheters; administration of total parenteral nutrition; previous antifungal therapy; previous therapy with glycopeptides; presence of oral/esophageal candidiasis; concomitant bacterial infections; neutropenia; Candida colonization, and concomitant AIDS-dementia complex. 2, 3 In addition, concerns about the emerging resistance of Candida species to azoles are increasing because of the extensive use of fluconazole treatment and prophylaxis in immunocompromised individuals. 2 
Case Report
We present here the case of a 35-year-old married female who presented with unexplained persistent fever and weight loss of more than 10% of body weight at Lok Nayak Hospital, New Delhi, India. One year prior, her husband was diagnosed HIV positive.
A blood sample was collected for HIV testing, culture, and hepatitis serology. HIV testing was done as per the national guidelines (National AIDS Control Organization [NACO] guidelines). 4 She was reactive for HIV-1. Blood culture was done on 5% sheep blood agar, heated blood agar, MacConkey agar, and Sabouraud dextrose agar, with and without chloramphenicol for isolation of bacteria and fungi, and the culture was sterile.
Her absolute CD4 T-lymphocyte count was 55 cells/mm 3 (flow cytometry using FACSCount system, Becton Dickinson San Jose, CA, USA) and plasma viral load was 220 000 copies/mL (AMPLICOR HIV-1 Monitor test, version 1.5, Roche Diagnostics Branchburg, NJ, USA). Per the NACO guidelines, 4 antiretroviral therapy (ART) was started for the patient. The patient was negative for hepatitis B antigen and anti-hepatitis C antibodies.
The patient's clinical condition started to improve 2 months after initiation of ART. The patient presented with white oral plaque-like lesions after 3 months of therapy. Oral swabs were obtained from the patient and subjected to direct microscopy and culture on Sabauraud dextrose agar. Direct microscopy showed oval budding cells with pseudohyphae. After 1 week of incubation, Candida species was isolated from the culture. On performing the germ tube test per the recommended procedure, 5 the isolate was germ tube positive and the differentiation between C albicans and C dubliniensis was done on the basis of morphology and chlamydospores formation on Staib Agar (SA) and caffeic acid-ferric citrate agar (CAF). 6 The Candida isolate did not formed chlamydospores on SA and CFA and formed smooth and shiny colonies on SA and could be identified as C albicans. DNA fingerprinting of the isolate was also performed by Southern hybridization and the isolate was reactive with C albicans-specific probe CARE-2. She was diagnosed with oral candidiasis, and fluconazole 100 mg/day was started. Her follow-up CD4 count increased to 211 cells/ mm 3 
months after initiation of ART.
Approximately 4 months after initiation of ART, she presented with fever. She was admitted to the hospital and all routine investigations for fever were done including blood culture for bacteria and fungi. Her white blood cell counts were 12 200/mm 3 and neutrophil count was 6630/mm 3 . After 4 days, she expired due to septic shock. Two days after her death, Candida species was isolated from blood culture on Sabauraud dextrose agar. This Candida isolate was speciated as C albicans by the similar tests performed for the above mentioned C albicans isolated from the oral thrush and found to be similar (by DNA fingerprinting) to the C albicans strain isolated from oral thrush (Figure 1) .
Antifungal susceptibility testing of both the isolates was performed for fluconazole by broth microdilution method 7 and spot assay. 8 The fluconazole concentration tested was 0.125 to 64 mg/mL. The interpretive breakpoints defined by the Clinical and Laboratory Standards Institute (CLSI) were used for fluconazole, and minimum inhibitory concentration (MIC) of 8 mg/mL and 64 mg/ml were classifieds as susceptible and resistant, respectively. 7 Both isolated C albicans strain showed a MIC > 64 mg/mL and found to be resistant to fluconazole.
Discussion
Candida species, the major pathogenic fungi, incite disease in hosts whose local or systemic immune system is deficient or damaged. Those most susceptible to the development of systemic candidiasis are patients with hematologic malignancies, postoperative patients, or individuals whose immune systems have been compromised. 9 Invasive fungal infections caused by Candida species have increased significantly. 1 Among the Candida species, C albicans is responsible for about half of all cases of candidemia but the proportion caused by NAC including C tropicalis, C glabrata, C parapsilosis, and C guilliermondii is also increasing. 1, 3, 10 Candidemia in itself and its potentially lethal complications including septic shock appear to be more common in patients with advanced HIV. 3, 11 Patients living with HIV infection have higher mortality from invasive fungal infection than those who were HIV-seronegative. 9 In the era of ART, a significant reduction in the incidence of all cases of candidemia has been observed in the post highly active antiretroviral therapy (HAART) with respect to pre-HAART period (0.09 episodes vs 1.1 per 100/py), but despite the use of HAART, candidemia still seems to be a severe complication of advanced stage of AIDS. 12 This is also reflected in the current case, in which the patient was diagnosed and treated for advanced stage HIV as shown by the adequate CD4 count increase after initiation of ART but still the patient died due to candidemia.
In our case, we lost time in diagnosis of candidemia by blood culture as detection of Candida species in blood culture depends on the volume of the blood samples and the relative concentration of Candida species within the bloodstream. Investigations other than blood culture, including Candida cell wall antigens such as mannans; Candida metabolites, particularly darabinitol; and Candida cytoplasmic antigen (Candida enolase and Candida heat shock protein [HSP]) may have helped for early diagnosis of candidemia. A strong index of suspicion of fungemia on the part of the clinician would go a long way as it has been seen that patients who received antifungal therapy not later than 48 hours after the onset of candidemia had a higher probability of survival compared with patients who did not receive antifungal therapy until at least 48 hours after the onset of candidemia. 9 Fluconazole has gained widespread use over the period of time leading to the emergence of fluconazole-resistant Candida species especially in HIV-infected patients, 9 as also seen in our case. Early diagnosis supported with antifungal susceptibility testing would be greatly beneficial in reducing patient morbidity outcome.
In conclusion, a high index of suspicion in high-risk patients for candidemia along with an early and aggressive management of the patient with antigen detection would go a long way in the management of these patients. Candida colonization is common in HIV-infected patients, especially in cases with CD4 counts <200 cells/mm 3 , leading to invasive infections in many such cases. 13 Guidelines for the treatment of candidiasis need to be re-evaluated, keeping in mind, the increasing emergence of resistance to azoles and need of treatment being given per individual antifungal susceptibility pattern.
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